Baird Medical Investment Holdings Ltd. announced its preliminary financial results for the six months ended June 30, 2024, reporting a significant increase in total revenues to US$13.1 million. This represents a 13.8% year-over-year growth, driven by the continued strength of its core business in China and initial traction in the U.S. market.
The company also achieved a net income of US$4.4 million for the first half of 2024, reflecting an impressive 85.8% year-over-year growth. These results underscore Baird Medical's disciplined approach to growth and operational efficiency.
Ms. Haimei Wu, Founder and CEO of Baird Medical, highlighted the substantial opportunity in the United States, where approximately 150,000 thyroidectomies are performed annually. The company's minimally invasive microwave ablation technology offers a promising alternative for patients with benign thyroid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.